Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line

NEXT STORY
Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
PREV STORY
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

CUE-101 Demonstrates Selective Binding and Preferential Activation/Expansion of Antigen-specific T Cells, Inhibition of Tumor ...

author_avatar
NASDAQ Market News

Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer

                                                                   Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer Amsterdam, The ...

author_avatar
NASDAQ Market News

Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program

Results confirm LPS Antagonist action of IMM-124E offers a novel therapeutic approach to induce ...

author_avatar
NASDAQ Market News